Cellular energy, stress responses, and aging research.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Mitochondria & aging: what the human evidence shows
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for mitochondria & aging: the best trial may be small, negative or about a different condition. No doses.
Peptide
Strongest human evidence in our sources
FDA
Human safety data
FDA-approved medicine (1)Approved for the specific uses on its label, which may not be this goal.
TAZPOWER (2021) · Human crossover trial + open extension Neither primary endpoint—six-minute walking distance or symptom score—was met in the blinded phase. Improvements appeared in the extension, with eight participants reaching 36 weeks. Limitation: An uncontrolled extension is less reliable for attributing benefit. Read the later FDA decision separately: accelerated approval used knee-muscle strength and requires confirmation of clinical benefit. Studied: 12 participants with Barth syndrome in the blinded phase.
FDA-approved
FDA label
Randomized human trials (2)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
Oral glutathione and body stores (2015) · Human randomized trial Glutathione increased in measured blood and cellular compartments in the supplemented groups and returned toward baseline after washout. Limitation: Biomarker changes are different from demonstrated disease prevention, improved survival, or broad “detox” benefits. Studied: 54 nonsmoking adults.
Carnosine in overweight and obese adults (2016) · Human randomized pilot trial The supplemented group showed attenuation of increases in fasting insulin and insulin resistance. A subgroup analysis reported glucose-tolerance changes. Limitation: Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease. Studied: 30 overweight or obese adults without diabetes.
Not approved
Trials only
Small or uncontrolled human studies (2)Human reports without randomization, such as pilots, case series or open-label studies.
Metabolic fate of intravenous NAD+ (2019) · Human metabolic pilot study The investigators did not observe an initial plasma increase during the first two hours. Urinary NAD+ and methyl-nicotinamide increased over the infusion period. Limitation: This was a metabolic-fate experiment, not a controlled clinical efficacy trial. It cannot establish anti-aging or cognitive benefit. Studied: Human volunteers in an intravenous-infusion pilot.
Thymalin and Epithalamin in older adults (2003) · Human clinical report with limited abstract methods The authors reported lower illness and mortality measures in treated groups. Limitation: Limited accessible methods and multiple preparations prevent a strong causal interpretation. Reported associations should not be presented as proof of lifespan extension. Studied: 266 elderly participants in a reported six-to-eight-year follow-up.
Not approved
Very limited
Animal and lab studies only (9)No human study in our sources.
5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT). Its featured evidence concerns cultured adipocytes and obese mice, rather than demonstrated weight loss in people.
Elamipretide targets mitochondrial biology. Its approved product, Forzinity, has a specific Barth syndrome indication rather than a general anti-aging use.
Epitalon, also spelled Epithalon, appears in telomerase and aging discussions. The selected study concerns cultured cells rather than a lifespan trial.
FOXO4-DRI is an experimental peptide designed to disrupt an interaction involved in senescent-cell survival. Its widely discussed aging findings come from cell and mouse experiments.
Glutathione is an endogenous tripeptide involved in redox biology. A six-month oral-supplement trial measured glutathione stores in several body compartments.
Humanin emerged from experiments examining neuronal cell survival. It is a research topic in mitochondrial and neurodegenerative biology, not an established dementia treatment.
L-Carnosine is a dipeptide investigated in metabolic and cellular research. A small oral-supplement pilot examined insulin and glucose-related measures in adults without diabetes.
NAD+ is a cofactor involved in cellular redox metabolism. A human pilot measured its metabolic fate during infusion; that experiment did not test longevity, cognition, or treatment of a disease.
Peptide bioregulators are very short synthetic peptides, two to four amino acids long, developed by Vladimir Khavinson and colleagues in St. Petersburg. Each is named for the tissue it was proposed to support. Almost all published research on them comes from that group and its collaborators.
Pinealon is a tripeptide investigated in experimental stress-response biology. The selected publication concerns cells under oxidative stress, rather than a clinical memory or dementia trial.
PNC-27 is a laboratory peptide built from part of the p53 tumor-suppressor protein attached to a cell-penetrating sequence. It has been studied in cancer-cell cultures and animal models. It is not an approved or human-tested cancer treatment.
SLU-PP-332 is a lab-made small molecule, not a peptide, that switches on the estrogen-related receptors involved in how muscle burns fuel. It is called an "exercise mimetic" because in mice it triggered some of the same metabolic changes as aerobic exercise. All published evidence comes from animal and cell studies.
Thymalin is a thymus-derived extract or peptide mixture. An older clinical report described long-term outcomes in elderly participants, but the abstract does not establish the methods needed for a firm causal longevity claim.
We check sellers’ lab reports with the testing labs themselves.
So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.
A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.